David H. Schwartz

8.4k total citations · 2 hit papers
118 papers, 6.6k citations indexed

About

David H. Schwartz is a scholar working on Virology, Immunology and Infectious Diseases. According to data from OpenAlex, David H. Schwartz has authored 118 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Virology, 40 papers in Immunology and 35 papers in Infectious Diseases. Recurrent topics in David H. Schwartz's work include HIV Research and Treatment (71 papers), HIV/AIDS drug development and treatment (23 papers) and Immune Cell Function and Interaction (20 papers). David H. Schwartz is often cited by papers focused on HIV Research and Treatment (71 papers), HIV/AIDS drug development and treatment (23 papers) and Immune Cell Function and Interaction (20 papers). David H. Schwartz collaborates with scholars based in United States, India and Switzerland. David H. Schwartz's co-authors include Bartley G. Hoebel, Robert F. Siliciano, Joseph B. Margolick, Tae‐Wook Chun, Diana Finzi, Karen Chadwick, Sujatha Iyengar, Geoffrey J. Gorse, Luis Hernández and James E. K. Hildreth and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

David H. Schwartz

117 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors

2000 771 citations David H. Schwartz et al. profile →
In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency

1995 613 citations David H. Schwartz et al. profile →

Peers

Countries citing papers authored by David H. Schwartz

Since Specialization

Citations

This map shows the geographic impact of David H. Schwartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Schwartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Schwartz more than expected).

Fields of papers citing papers by David H. Schwartz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Schwartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Schwartz. The network helps show where David H. Schwartz may publish in the future.

Co-authorship network of co-authors of David H. Schwartz

This figure shows the co-authorship network connecting the top 25 collaborators of David H. Schwartz. A scholar is included among the top collaborators of David H. Schwartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Schwartz. David H. Schwartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment with a Rho Kinase Inhibitor Improves Survival from Graft-Versus-Host Disease in Mice after MHC-Haploidentical Hematopoietic Cell Transplantation 2014 ·Biology of Blood and Marrow Transplantation ·Sujatha Iyengar, (unknown), (unknown), Robert Korngold, David H. Schwartz	9
2	Potentiation of EBV-Induced B Cell Transformation by CXCR4-Tropic, But Not CCR5-Tropic, HIV gp120: Implications for HIV-Associated Lymphomagenesis 2010 ·AIDS Research and Human Retroviruses ·Sujatha Iyengar, David H. Schwartz	5
3	Epitope Enhancement of a CD4 HIV Epitope toward the Development of the Next Generation HIV Vaccine 2006 ·The Journal of Immunology ·Takahiro Okazaki, C D Pendleton, Pablo Sarobe, Elaine K. Thomas, Sujatha Iyengar, Clayton Harro, David H. Schwartz, Jay A. Berzofsky	10
4	Erythropoietic Response to Anemia in Chronic Hepatitis C Patients Receiving Combination Pegylated Interferon/Ribavirin 2005 ·The American Journal of Gastroenterology ·Vijayan Balan, David H. Schwartz, George Y. Wu, Andrew J. Muir, Reem Ghalib, (unknown), Emmet B. Keeffe, Lorenzo Rossaro, (unknown), Betty L. Goon, Peter Bowers, G Leitz, (unknown)	49
5	Comparison of Systemic and Mucosal Delivery of 2 Canarypox Virus Vaccines Expressing either HIV‐1 Genes or the Gene for Rabies Virus G Protein 2004 ·The Journal of Infectious Diseases ·Peter F. Wright, Jiří Městecký, M. Juliana McElrath, Michael C. Keefer, Geoffrey J. Gorse, Paul A. Goepfert, Zina Moldoveanu, David H. Schwartz, Paul Spearman, Raphaëlle El Habib, Michele Spring, Yuwei Zhu, Carol Smith, Jorge Flores, Kent J. Weinhold	45
6	HIV-2 Subtype Circulating in India (South) 2003 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Rajesh Kannangai, Shaji R Velayudhan, Sandeep Ramalingam, M V Jesudason, (unknown), Renu George, (unknown), David H. Schwartz, Gopalan Sridharan	21
7	QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans 2001 ·Vaccine ·Thomas G. Evans, M. Juliana McElrath, Thomas J. Matthews, David C. Montefiori, Kent J. Weinhold, Mark Wolff, Michael C. Keefer, Esper G. Kallás, Lawrence Corey, Geoffrey J. Gorse, Robert B. Belshe, Barney S. Graham, Paul Spearman, David H. Schwartz, Mark J. Mulligan, Paul A. Goepfert, Patricia Fast, (unknown), Michael F. Powell, Don Francis	106
8	A peptide enzyme linked immunosorbent assay (ELISA) for the detection of human immunodeficiency virus type-2 (HIV-2) antibodies: an evaluation on polymerase chain reaction (PCR) confirmed samples 2001 ·Journal of Clinical Virology ·Rajesh Kannangai, Sandeep Ramalingam, (unknown), O C Abraham, Renu George, Renan C. Castillo, David H. Schwartz, M V Jesudason, G Sridharan	19
9	Immunization with Recombinant Canarypox Vectors Expressing Membrane-Anchored Glycoprotein 120 Followed by Glycoprotein 160 Boosting Fails to Generate Antibodies That Neutralize R5 Primary Isolates of Human Immunodeficiency Virus Type 1 2000 ·AIDS Research and Human Retroviruses ·(unknown), Alicia Gaitan, Tuofu Zhu, Cecilia Graziosi, Kathryn M. McGrath, James Tartaglia, Pierre Caudrelier, Raphaëlle El Habib, Michel Klein, Adriano Lazzarin, Donald M. Stablein, (unknown), Lawrence Corey, Michael Greenberg, David H. Schwartz, David C. Montefiori	129
10	Increase in plasma IL-10 levels and rapid loss of CD4+ T cells among HIV-infected individuals in south India 2000 ·International Journal of STD & AIDS ·Padma Srikanth, Renan C. Castillo, Gopalan Sridharan, T. Jacob John, Anand Zachariah, Dilip Mathai, David H. Schwartz	25
11	Differential inhibition of neointimal thickening after balloon injury in the rabbit aorta by glycosaminoglycans 1998 ·Journal of the American College of Cardiology ·David H. Schwartz, (unknown), (unknown), (unknown), (unknown), (unknown), Richard Eisenberg	1
12	Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type 1 1996 ·The Journal of Infectious Diseases ·John R. Mascola, S W Snyder, O. S. Weislow, Solomon Belay, Robert B. Belshe, David H. Schwartz, M L Clements, Raphael Dolin, Barney S. Graham, Geoffrey J. Gorse, M. C. Keefer, M. Juliana McElrath, Mary Clare Walker, K Wagner, John G. McNeil, Francine E. McCutchan, Donald S. Burke, (unknown)	354
13	Determinants Of Antibody Response After Recombinant Gp160 Boosting In Vaccinia-Naive Volunteers Primed With Gp160-Recombinant Vaccinia Virus 1994 ·The Journal of Infectious Diseases ·Barney S. Graham, Geoffrey J. Gorse, David H. Schwartz, M. C. Keefer, M. Juliana McElrath, Thomas J. Matthews, Peter F. Wright, Robert B. Belshe, M L Clements, Raphael Dolin, Lawrence Corey, Dani P. Bolognesi, D Stablein, Joy Esterlitz, Shiu-Lok Hu, Gale Smith	29
14	Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans 1994 ·AIDS Research and Human Retroviruses ·Michael C. Keefer, Barney S. Graham, Robert B. Belshe, David H. Schwartz, Lawrence Corey, Dani P. Bolognesi, Donald M. Stablein, David C. Montefiori, (unknown), M L Clements, Geoffrey J. Gorse, Peter F. Wright, Thomas J. Matthews, Gale Smith, Dale N. Lawrence, Raphael Dolin	46
15	Absence of Recoverable Infectious Virus and Unique Immune Responses in an Asymptomatic HIV ⁺ Long-Term Survivor 1994 ·AIDS Research and Human Retroviruses ·David H. Schwartz, Usha Sharma, Michael Busch, Kent J. Weinhold, Thomas J. Matthews, Judy Lieberman, Deborah L. Birx, (unknown), Joseph B. Margolick, Thomas C. Quinn, Brian M. Davis, Omar Bagasra, Roger J. Pomerantz, Raphael P. Viscidi	63
16	Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. 1993 ·Journal of Clinical Investigation ·Seth H. Pincus, (unknown), David H. Schwartz, George K. Lewis, Barney S. Graham, William A. Blattner, George U. Fisher	48
17	V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. 1993 ·Journal of Clinical Investigation ·David C. Montefiori, Barney S. Graham, Jin Tao Zhou, (unknown), David H. Schwartz, Lisa A. Cavacini, Marshall R. Posner	58
18	Specific Activation Strategies for Amplification of Low CTL Signals 1992 ·AIDS Research and Human Retroviruses ·K J Weinhold, J. Tartaglia, Enzo Paoletti, (unknown), David H. Schwartz, M. Juliana McElrath, Nia Roberts, Geoffrey J. Gorse	5
19	Detection and Quantification of Human Immunodeficiency Virus RNA in Patient Serum by Use of the Polymerase Chain Reaction 1991 ·The Journal of Infectious Diseases ·Mark Holodniy, David Katzenstein, Sabyasachi Sengupta, (unknown), (unknown), David H. Schwartz, (unknown), (unknown), T. C. Merigan	133
20	Induction of neonatal tolerance to H-2k in B6 mice does not allow the emergence of T cells specific for H-2k plus vaccinia virus. 1982 ·The Journal of Experimental Medicine ·David H. Schwartz, Peter C. Doherty	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact